B. I. Rini, G. Wilding, G. Hudes, W. M. Stadler, S. Kim, J. Tarazi, B. Rosbrook, P. C. Trask, L. Wood and J. P. Dutcher, “Phase II Study of Axitinib in Sorafenib- Refractory Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 27, No. 27, 2009, pp. 4462-4468. doi:10.1200/JCO.2008.21.7034

has been cited by the following article:

• TITLE: Tumor Resistance to Molecularly Targeted Agents

  AUTHORS: James Chen, Peter S. Edelstein, Philip J. Johnson, Robert Lustig, Lucien Ooi

  KEYWORDS: Tumor Resistance, Signaling Pathway, Gene Pathway, Oncogene, Renal Cell Carcinoma

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.2, July 8, 2011

  ABSTRACT: Despite the development of new targeted cancer therapies, primary and secondary tumors continue to be a leading cause of suffering and mortality worldwide. The complexity and heterogeneity of malignancies ultimately result in tumor resistance to therapies, such as EGFR inhibitiors, anti-angiogenesis agents, and tyrosine kinase inhibitors. An example of targeted therapies for renal cell carcinoma is presented, including the SAE profile and efficacy of 6 targeted agents. Although survival is improved, resistance and an increased side effect profile diminish the benefits of these agents. New agents are needed which are pathway independent and which can overcome tumor resistance without adding to the side effect profile of current therapies.